Kelaiying Pharmaceutical Group (Tianjin) Co., Ltd. 2025 Annual Report Summary
Securities Code: 002821 Securities Abbreviation: Kelaiying Announcement Number: 2026-006
I. Important Notes This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial position, and future development plans, investors should carefully read the full annual report in the media designated by the China Securities Regulatory Commission. All directors attended the board meeting that reviewed this report. Non-standard audit opinion notice □ Applicable Not applicable Board of Directors' resolution on the profit distribution plan or capital reserve to share capital increase plan for the reporting period ☑ Applicable Not applicable Whether to transfer capital reserve to share capital □ Yes No The profit distribution plan reviewed and approved by the Board of Directors is as follows: Based on the total share capital entitled to profit distribution on the equity registration date when the distribution plan is implemented, a cash dividend of RMB 13 per 10 shares (tax inclusive) will be distributed to all shareholders, with 0 bonus shares (tax inclusive), and no transfer of capital reserve to share capital. Board of Directors' resolution on the preferred share profit distribution plan for the reporting period □ Applicable Not applicable
II. Company Basic Information
- Company Profile Stock Abbreviation: Kelaiying Stock Exchange: Shenzhen Stock Exchange Stock Code: 002821. SZ/06821. HK Contact Person and Contact Information Name: Xu Xiangke Title: Board Secretary Securities Affairs Representative: Yu Changliang Office Address: No. 71, Seventh Avenue, Tianjin Economic-Technological Development Area Fax: 022-66252777 Telephone: 022-66389560 Email: securities@asymchem.com.cn Address: No. 71, Seventh Avenue, Tianjin Economic-Technological Development Area Fax: 022-66252777 Telephone: 022-66389560 Email: securities@asymchem.com.cn